Posted by Michael Wonder on 12 Jun 2025
Radiopharm Theranostics granted US FDA fast track designation for RAD101 imaging in brain metastases
11 June 2025 - Radiopharm Theranostics today announced that the US FDA has granted fast track designation for RAD101 to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumours of different origin including leptomeningeal disease.
RAD101 is the Company’s novel imaging small molecule that targets fatty acid synthase, a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumours, including cerebral metastases.
